to reduce newly acquired HIV infections by 25 per cent by 2009 to achieve annual reductions in the notification rates of gonorrhoea, infectious syphilis and chlamydia infections among priority populations to reduce the physical and psychological disorders and associated disabilities in people living with HIV/ AIDS to decrease the number of late diagnoses of HIV infection by 25 per cent by 2009 to achieve successive annual reductions in AIDS-related deaths by 2009 to increase the number and distribution of clinicians authorised to prescribe highly specialised oral HIV drugs under section 100 of the National Health Act, 1953 across NSW to increase the number of general practitioners involved in HIV care by 20 per cent by 2009.
The introduction of these targets establishes measurable health outcomes that decision makers can use to monitor the impact of the NSW HIV/AIDS program and inform the allocation of resources.
The challenges that face NSW in the future include: safeguarding gains in HIV prevention among injecting drug users, Aboriginal people and sex workers reducing HIV infections among inner city gay men addressing synergy between HIV and sexually transmissible infections (on the basis of research that shows that some sexually transmissible infections can facilitate HIV transmission) reducing new HIV infections and improving early diagnosis.
HIV treatmeNt
Combining multiple drugs in treatment regimens known as Highly Active Anti-Retroviral Therapy (HAART) results in large reductions in HIV viral load in previously untreated patients. This has revolutionized treatment outcomes, with 3 The highest notification rate for HIV in 2004 was in NSW (5.9 cases per 100,000), followed by Victoria (4.3 cases per 100,000) and Queensland (3.4 cases per 100,000). In NSW, 'men who have sex with men' remains the largest exposure category for patients with HIV infection, and in 2004 accounted for 62 per cent of total cases. Heterosexual many patients continuing to achieve viral suppression for more than seven years after initiation of HAART.
However, HAART is associated with an increased rate of cardiovascular morbidity, proportionate to the duration of therapy. This has prompted enhanced efforts to control cardiovascular risk factors in HIV patients, in particular the management of lipid levels, smoking, diabetes and hypertension. More recently licensed antiretroviral drugs have demonstrated variable impact on lipid levels and may provide advantages over earlier agents.
The emergence of resistance to HIV drugs results from mutation. Initially the virus experiences a change in the genetic code and this results in structural change to the target of the drug, usually a critical enzyme or outer component of the HIV virus.
To combat drug resistance, scientists have attempted to develop drugs that target other stages of the viral life cycle. Some of these strategies look promising. Studies of new protease inhibitors and non-nucleoside reverse transcriptase inhibitors suggest that they may be beneficial in patients who have developed resistance.
Studies to develop effective vaccines are underway in many countries, including Australia; however, it is likely to be many years before an effective vaccine will be available. In addition, controversy surrounds the level of vaccine efficacy that would be needed to justify a vaccination campaign. If the protection rate were only modest, there would be a risk of producing a false sense of protection among those who were vaccinated.
